CA Stock MarketDetailed Quotes
AQS Aequus Pharmaceuticals Inc
- 0.030
- 0.0000.00%
15min DelayMarket Closed Jul 12 16:00 ET
3.98MMarket Cap-2000P/E (TTM)
0.000High0.000Low0Volume0.000Open0.030Pre Close0.00Turnover0.05552wk High0.00%Turnover Ratio132.63MShares0.01052wk Low-0.015EPS TTM3.38MFloat Cap0.800Historical HighLossP/E (Static)112.80MShs Float0.010Historical Low-0.02EPS LYR0.00%Amplitude--Dividend TTM-0.81P/B1Lot Size--Div YieldTTM
Aequus Pharmaceuticals Inc Key Stats
Quarterly+Annual
YOY
| (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | (Q2)Jun 30, 2022 | (Q1)Mar 31, 2022 | (FY)Dec 31, 2021 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -95.40%-521.7K | -17.48%-2.29M | -102.06%-902.11K | -130.56%-266.99K | -66.57%-1.95M | -446.47K | -185.53%-539.02K | -75.19%-851.29K | -289.43%-115.8K | -45.63%-1.17M |
| Net income from continuing operations | 11.05%-662.09K | 7.64%-2.96M | 29.86%-715.87K | 18.82%-744.32K | -77.39%-3.21M | ---1.02M | -31.17%-500.47K | -61.18%-772.11K | -47.49%-916.89K | -73.11%-1.81M |
| Operating gains losses | ---- | 100.21%88 | -439,600.00%-4.4K | ---- | -1,154.85%-41.16K | --1 | ---32.84K | ---15.6K | --7.28K | ---3.28K |
| Depreciation and amortization | -4.79%33.08K | 6.42%138.16K | -2.57%33.92K | 9.71%34.75K | 1.34%129.83K | --34.82K | -17.73%31.67K | -14.50%31.67K | -1.53%31.67K | -39.28%128.11K |
| Asset impairment expenditure | ---- | --0 | ---- | ---- | --566.76K | ---- | ---- | ---- | ---- | --0 |
| Remuneration paid in stock | 70.02%7.86K | 24.36%50.92K | 104.13%8.84K | -76.49%4.62K | -81.02%40.94K | --4.33K | -98.28%756 | -67.82%16.21K | -79.13%19.65K | -27.51%215.76K |
| Other non cashItems | -11.05%15.24K | -42.44%66.49K | -15.93%16K | -73.65%17.13K | -56.87%115.53K | --19.04K | -93.71%4.55K | -57.91%26.92K | -1.90%65.02K | 5.65%267.88K |
| Change In working capital | -79.99%84.21K | -6.84%415.08K | -373.39%-240.61K | -37.88%420.83K | 1,441.02%445.57K | ---50.83K | -193.78%-42.69K | 12.54%-138.37K | 69.66%677.46K | 105.54%28.91K |
| -Change in receivables | -101.44%-4.44K | -54.97%278.41K | 208.34%38.14K | -54.11%308.17K | 469.56%618.23K | ---35.2K | 145.31%16.69K | 76.71%-34.81K | 128.22%671.54K | 25.06%-167.29K |
| -Change in inventory | 86.22%46.31K | -165.05%-29.92K | 67.04%60.61K | 145.72%24.87K | 378.74%46K | --36.28K | 152.72%25.65K | -348.44%-26.05K | -27.66%10.12K | 86.00%-16.5K |
| -Change in prepaid assets | -105.94%-9.22K | 208.18%138.98K | 108.15%11.07K | 316.10%155.33K | -280.81%-128.47K | ---135.87K | -148.03%-26.71K | 111.06%105.98K | -116.62%-71.88K | 183.41%71.05K |
| -Change in payables and accrued expense | 176.34%51.56K | 130.62%27.61K | -517.38%-350.43K | -199.79%-67.54K | -163.67%-90.19K | --83.96K | -177.35%-58.32K | -164.06%-183.51K | -45.53%67.68K | 248.47%141.65K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -95.40%-521.7K | -17.48%-2.29M | -102.06%-902.11K | -130.56%-266.99K | -66.57%-1.95M | ---446.47K | -185.53%-539.02K | -75.19%-851.29K | -289.43%-115.8K | -45.63%-1.17M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 0 | 0 | -4,024.06%-507.96K | |||||||
| Net PPE purchase and sale | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | 66.54%-4.12K |
| Net intangibles purchas and sale | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --0 | --0 | ---- |
| Net investment purchase and sale | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---503.84K |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --0 | --0 | -4,024.06%-507.96K |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 867.32%593.55K | 1,270.46%2.21M | 1,511.63%960.29K | 262.67%61.36K | -107.89%-189.19K | -68.03K | -2.50%-37.72K | -105.80%-45.72K | -102.24%-37.72K | 16.87%2.4M |
| Net issuance payments of debt | 867.32%593.55K | 1,270.46%2.21M | 1,511.63%960.29K | 262.67%61.36K | -28.26%-189.19K | ---68.03K | -2.50%-37.72K | -24.24%-45.72K | -2.50%-37.72K | -42.07%-147.51K |
| Net common stock issuance | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --0 | --0 | 18.09%2.55M |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 867.32%593.55K | 1,270.46%2.21M | 1,511.63%960.29K | 262.67%61.36K | -107.89%-189.19K | ---68.03K | -2.50%-37.72K | -105.80%-45.72K | -102.24%-37.72K | 16.87%2.4M |
| Net cash flow | ||||||||||
| Beginning cash position | -31.87%170.2K | -89.55%249.82K | -86.16%112.02K | -89.75%249.82K | 42.86%2.39M | --809.16K | -61.80%1.39M | -31.60%2.28M | 41.75%2.44M | 245.51%1.67M |
| Current changes in cash | 134.94%71.85K | 96.28%-79.62K | 111.31%58.18K | -33.94%-205.63K | -398.48%-2.14M | ---514.5K | 22.32%-576.74K | -408.56%-897.01K | -109.49%-153.52K | -41.87%717.56K |
| End cash Position | 447.85%242.04K | -31.87%170.2K | -31.87%170.2K | -98.06%44.18K | -89.55%249.82K | --249.82K | -71.96%809.16K | -61.80%1.39M | -31.60%2.28M | 39.14%2.39M |
| Free cash from | -95.40%-521.7K | -17.48%-2.29M | -102.06%-902.11K | -130.56%-266.99K | -65.99%-1.95M | ---446.47K | -167.10%-539.02K | -71.12%-851.29K | -78.48%-115.8K | -43.94%-1.18M |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | -- | -- | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
Heat List
CA
Overall
Symbol
Latest Price
%Chg